» Articles » PMID: 27348071

Microbial Biofilms in Pulmonary and Critical Care Diseases

Overview
Specialty Pulmonary Medicine
Date 2016 Jun 28
PMID 27348071
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Microbial biofilms can colonize medical devices and human tissues, and their role in microbial pathogenesis is now well established. Not only are biofilms ubiquitous in natural and human-made environments, but they are also estimated to be associated with approximately two-thirds of nosocomial infections. This multicellular aggregated form of microbial growth confers a remarkable resistance to killing by antimicrobials and host defenses, leading biofilms to cause a wide range of subacute or chronic infections that are difficult to eradicate. We have gained tremendous knowledge on the molecular, genetic, microbiological, and biophysical processes involved in biofilm formation. These insights now shape our understanding, diagnosis, and management of many infectious diseases and direct the development of novel antimicrobial therapies that target biofilms. Bacterial and fungal biofilms play an important role in a range of diseases in pulmonary and critical care medicine, most importantly catheter-associated infections, ventilator-associated pneumonia, chronic Pseudomonas aeruginosa infections in cystic fibrosis lung disease, and Aspergillus fumigatus pulmonary infections.

Citing Articles

Immunological Effects of Electronic Cigarette Use: A Review of Current Evidence.

Zima K, Bogucka A, Wojtas M, Zabielska-Kaczorowska M Clin Rev Allergy Immunol. 2025; 68(1):9.

PMID: 39891861 DOI: 10.1007/s12016-025-09026-5.


Pulsed electric field at resonance frequency combat Klebsiella pneumonia biofilms.

Mohamed D, Mohammed H, El-Gebaly R, Adam M, Ali F Appl Microbiol Biotechnol. 2024; 108(1):505.

PMID: 39500784 PMC: 11538251. DOI: 10.1007/s00253-024-13330-z.


Artificial Intelligence to Close the Gap between Pharmacokinetic/Pharmacodynamic Targets and Clinical Outcomes in Critically Ill Patients: A Narrative Review on Beta Lactams.

Goncalves Pereira J, Fernandes J, Mendes T, Gonzalez F, Fernandes S Antibiotics (Basel). 2024; 13(9).

PMID: 39335027 PMC: 11428226. DOI: 10.3390/antibiotics13090853.


Virulence of Burkholderia pseudomallei ATS2021 Unintentionally Imported to United States in Aromatherapy Spray.

Cote C, Mlynek K, Klimko C, Biryukov S, Mou S, Hunter M Emerg Infect Dis. 2024; 30(10):2056-2069.

PMID: 39320153 PMC: 11431913. DOI: 10.3201/eid3010.240084.


State-of-the-Art Review on Inhalable Lipid and Polymer Nanocarriers: Design and Development Perspectives.

Costabile G, Conte G, Brusco S, Savadi P, Miro A, Quaglia F Pharmaceutics. 2024; 16(3).

PMID: 38543241 PMC: 10975237. DOI: 10.3390/pharmaceutics16030347.


References
1.
Yau Y, Ratjen F, Tullis E, Wilcox P, Freitag A, Chilvers M . Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients. J Cyst Fibros. 2014; 14(2):262-6. DOI: 10.1016/j.jcf.2014.09.013. View

2.
Martins M, Henriques M, Lopez-Ribot J, Oliveira R . Addition of DNase improves the in vitro activity of antifungal drugs against Candida albicans biofilms. Mycoses. 2011; 55(1):80-5. PMC: 3175262. DOI: 10.1111/j.1439-0507.2011.02047.x. View

3.
Luna C, Sibila O, Agusti C, Torres A . Animal models of ventilator-associated pneumonia. Eur Respir J. 2009; 33(1):182-8. DOI: 10.1183/09031936.00046308. View

4.
Moskowitz S, Emerson J, McNamara S, Shell R, Orenstein D, Rosenbluth D . Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection. Pediatr Pulmonol. 2010; 46(2):184-92. PMC: 3479399. DOI: 10.1002/ppul.21350. View

5.
Kalia D, Merey G, Nakayama S, Zheng Y, Zhou J, Luo Y . Nucleotide, c-di-GMP, c-di-AMP, cGMP, cAMP, (p)ppGpp signaling in bacteria and implications in pathogenesis. Chem Soc Rev. 2012; 42(1):305-41. DOI: 10.1039/c2cs35206k. View